ACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
|
|
- Shon Todd
- 5 years ago
- Views:
Transcription
1 ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
2 No disclosures
3 Objectives Overview Cases Current Therapy Risk stratification: phenotypes AHF studies Future therapeutic agents
4 Case 1 78 yo male c/o SOB 187/ % RA 98.6F PE: JVD, rales, peripheral edema A. Diuretic, NTG, CPAP B. Diuretic, CPAP C. NTG, CPAP D. Dobutamine, CPAP
5 Case 2 78 yo male c/o SOB 132/ % RA 98.6F PE: JVD, peripheral edema A. Diuretic, NTG, CPAP B. Diuretic, CPAP C. NTG, CPAP D. Dobutmaine, CPAP
6 Case 3 78 yo male c/o SOB 89/ % RA 98.6F PE: JVD, rales, peripheral edema, ALOC A. Diuretic, NTG, CPAP B. Diuretic, CPAP C. NTG, CPAP D. Dobutamine, CPAP
7 AHF: Epidemic Major public health concern Hospitalizations 1 million /year 80% via ED Cost: $32 billion/year Significant M&M High recidivism
8 Hospitalization Predicts early death and readmissions Mortality rates 5-15 x more likely to die first year 3 6 months mortality 10%-20% I year mortality 22%-32% Recurrent admissions for decomposition 35% readmitted at days
9 Current Therapies 40 years Modestly effective at best Same medications NTG, Diuretics, Inotropes Not improve In-hospital or Post-discharge survival rates or Decreased readmissions No mitigation in mortality rate Unlike ACS and CVA
10 Acute Heart Failure NOT a single disease entity Single therapy NOT efficacious Individualize therapy Not everyone gets Diuretic Vasodilator Inotrope Recognize: syndrome Heterogeneous Numerous comorbidities Emphasis Clinical phenotypes Therapy Clinical findings and Initial systolic blood pressure
11 Current HF Therapies Chronic LV HF Well established guidelines ARBs, ACEI, beta-blocker Improved outcomes AD HF No improvement in outcomes Loop diuretics Class I recommendation Vasodilators Inotropes Short term feel better No long term impact
12 Acute Heart Failure CONGESTION Majority Pulmonary or systemic congestion Caused by elevated LV filling pressure SOB, JVD, peripheral edema EF > 50% : preserved LV systolic function LOW CARDIAC OUTPUT Uncommon but high mortality rate Circulatory failure Fatigue, N/V, ALOC, SOB, reduced exercise capacity Severe LV systolic dysfunction EF < 20%
13 Precipitating Factors in AHF Cardiac Afib with RVR Ischemia, ACS Arrhythmias Valvular disease Myopathies Uncontrolled HTN Non-cardiac COPD, Asthma, Pneumonia Noncompliance CRI, Anemia TH, DM CVA Surgery Alcohol, Drugs
14 Therapeutic Goals Improve signs and symptoms ED First 6-12 hours Improve quality of life Short term Improve post discharge outcomes Long term
15 Treatment Emphasis Initiate early therapy Maintain oxygenation Prevent intubation Improve clinical symptoms Prevent infarction
16 AHF Disease Stratification 3 phenotypes Based on systolic blood pressure on presentation Hypertensive Normotensive Hypotensive
17 Target therapy by phenotype Systolic BP (mmhg) Hypertensive > 160 Normotensive Hypotensive < 100 First agent Vasodilators Loop diuretics Inotropes
18 Hypertensive AHF Vascular failure Sbp > 160 mm Hg Develops over hours Preserved EF > 50% Increased SVR Pulmonary congestion respiratory distress, rales, orthopnea O2 saturation < 90% Pulmonary edema Extreme form Agents Vasodilators First line treatment Adjunct therapy Loop diuretics
19 Pharmacological therapy: HTN AHF Nesiritide: rbnp VMAC study (+) ASCEND-HF trial (+/-- ) Rose study (-) Neutral Neither unsafe or efficacious Serelaxin: rhr-2 RELAX-AHF (+) Peptide regulates maternal adaptation to pregnancy Reduces signs and symptoms of congestion Reduces 180-day CV mortality Reduces all cause mortality by 37%
20 Vasodilators Serelaxin Increases renal function Improves vascular compliance Improves cardiac output Relaxin Improves dyspnea Improves congestion No improvement in rehospitalization rate PRE-RELAX-AHF (+) RELAX-AHF 2
21 Serelaxin and Relaxin Beneficial effects on dyspnea and post discharge clinical outcomes Decreased LOS Decrease in worsening of HF inpatient Improved signs and symptoms inpatient Supported by biomarker changes Hs-Toponin T, Cystatin C, NT- probnp Given early Within 16 hours (window of time) Prevent end-organ damage Long-term end organ protection No benefit
22 Normotensive AHF Acutely decompensated systolic or diastolic CHF Normal blood pressure Develops over days or weeks Chronic HF Systemic congestion Primarily Pulmonary congestion Minimal Agents Loop diuretics First- line therapy Peripheral edema Common
23 Hypotensive AHF Low cardiac output Sbp < 100 mmhg EF < 20% Decreased renal function Poor renal blood flow Congestion Subtle Cardiogenic shock Extreme form Agents Dobutamine First line treatment ALOC, lethargy, abdominal pain, muscle aches
24 Pharmacological Therapy: Hypotensive AHF Inotrope: mainstay Enhance cardiac contractility Dobutamine, milrinone, levosimendan (Europe) Alleviate symptoms Compromised vital organ perfusion and hypotension DAD-HF trial and ROSE trial: dopamine (-) Milrinone and Levosimendan serious adverse effects Limited efficacy in improving signs and symptoms OMTIME-CHF Milrinone : first large scale (-) REVIVE-1 and REVIVE-2 trials and SURVIVE study Levosimendan : (-) Dobutamine (-)
25 Omecamtiv mecarbil Novel inotropic agent Cardiac myosin activator Direct effects on sarcomere Dyspnea response rate improved ESC 2013 (+) ATOMIC HF (+) (+) Intracellular Ca2+ not increased No pro-arrhythmic potential COSMIC-HF Ongoing Oral form Improved stroke volume
26 CART analysis and ADHERE data Correlation of systolic BP and outcomes for AHF Sbp < 115 mmhg Worse in-hospital prognosis Sbp > 160 mm Hg Good myocardial contractile reserve Better outcomes Pharmacological agents Currently initiated In-hospital 24 hours Implement early < 16 hours in ED
27 Non-invasive ventilation CPAP vs BIPAP Maintain oxygenation Prevent intubation Feel better faster Clinically oriented outcome Decreases work of breathing Increases intra-thoracic pressures > cardiac output Studies Neutral but lack of harm
28 BIOMAKERS BNP Delta Fall of 30% NT-pro BNP Higher levels Poor prognosis Identify high risk patients Aggressive therapy Disease severity Troponin Cr and Cystatin C Renal marker for injury ST2 fibrosis markers heart Galectin-3 fibrosis markers Heart Copeptin: newest Vasopressin peptide Hormone in HF Tailor therapy Receptor vasopressin antagonist
29 Case 1 78 yo male c/o SOB 187/ % RA 98.6F PE: JVD, rales, peripheral edema A. Diuretic, NTG, CPAP B. Diuretic, CPAP C. NTG, CPAP D. Dobutamine, CPAP
30 Case 2 78 yo male c/o SOB 132/ % RA 98.6F PE: JVD, peripheral edema A. Diuretic, NTG, CPAP B. Diuretic, CPAP C. NTG, CPAP D. Dobutmaine, CPAP
31 Case 3 78 yo male c/o SOB 89/ % RA 98.6F PE: JVD, rales, peripheral edema, ALOC A. Diuretic, NTG, CPAP B. Diuretic, CPAP C. NTG, CPAP D. Dobutmaine, CPAP
32 Overview Heterogenous syndrome Based on 3 phenotypes HTN > 160 Normotensive Hypotensive < 100 Vasodilator Loop diuretic Inotrope Initiate therapy early CPAP/ BIPAP Future agents Initiate in ED
33 Questions
Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationManagement of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU
Management of acute decompensated heart failure and cardiogenic shock Arintaya Phrommintikul Department of Medicine CMU Acute heart failure: spectrum Case 64 y/o M with Hx of non-ischemic DCM (LVEF=25-30%)
More informationDIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE
DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE Mefri Yanni, MD Bagian Kardiologi dan Kedokteran Vaskular RS.DR.M.Djamil Padang The 3rd Symcard Padang, Mei 2013 Outline Diagnosis Diagnosis Treatment options
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationMANAGEMENT OF ACUTE PULMONARY EDEMA. Pr. NOUIRA Semir Emergency Department Fattouma Bourguiba University Hospital
MANAGEMENT OF ACUTE PULMONARY EDEMA Pr. NOUIRA Semir Emergency Department Fattouma Bourguiba University Hospital ACUTE HEART FAILURE 35% 10% Goals of Acute Management Rapidly improve symptoms while preserving
More informationACUTE HEART FAILURE in the ED. Pr. Samir Nouira Emergency Department Fattouma Bourguiba University Hospital Monastir Tunisia
ACUTE HEART FAILURE in the ED Pr. Samir Nouira Emergency Department Fattouma Bourguiba University Hospital Monastir Tunisia ACUTE HEART FAILURE 80% Acute Heart Failure Syndrome Sensitivity Specificity
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationState of the Art: acute heart failure Is it just congestion?
ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationΟξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;
Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationDiagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta
Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationAcute heart Failure. Critical cardiac care: update Markku S. Nieminen Helsinki, Finland. M S Nieminen, AHF ,ESC Stockholm
Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen Helsinki, Finland M S Nieminen, AHF 300810,ESC Stockholm Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen
More information2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland
2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland Disclosures Consultancy fees and speaker s honoraria from: Amgen, Servier, Novartis, Johnson & Johnson, Merck, Berlin Chemie,
More informationStopping the Revolving Door of ADHF
Stopping the Revolving Door of ADHF Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationHeart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital
Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital Disclosures Chair or Committee Member of trials or registries sponsored by Novartis, Bayer, Cardiorentis, Servier
More informationBehandeling van Hartfalen: over 5 jaar
Behandeling van Hartfalen: over 5 jaar Adriaan Voors, cardioloog UMCG Over 5 jaar Heart Failure Treatment in 5 Years HFrEF: best evidence, biggest pipeline Entresto Omcamtiv LVAD: destination therapy HFrEF:
More informationQuestion by Question (QXQ) Instructions for the HCHS/SOL Heart Failure Diagnosis Form (HFD)
Question by Question (QXQ) Instructions for the HCHS/SOL Heart Failure Diagnosis Form (HFD) A Heart Failure Diagnosis (HFD) Form is filled out by the reviewer for all case packets that are sent to them
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationAcute HF is a complex and often life-threatening clinical condition. 1 Existing
ACUTE HEART FAILURE: WHAT IS NEW? John Parissis, MD, PhD; Vasiliki Bistola, MD Author affiliations: Heart Failure Unit, University of Athens, Athens, Greece Address for correspondence: John Parissis, Navarinou
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationCase Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More information9/14/2017 HEART FAILURE IN OBS NO RELEVANT DISCLOSURES IRRELEVANT DISCLOSURES OBJECTIVES WHY HEART FAILURE
HEART FAILURE IN OBS Matthew Wheatley MD, FACEP Grady Memorial Hospital Emory University School of Medicine NO RELEVANT DISCLOSURES 52 y.o. female with HTN, DM and CHF presents with DIB. She states she
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationRenal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial
Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Background AHF + Renal
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationHow to define the target population?
Heart Failure 2011 22-24 May. Gothenburg, Sweden Mortality or morbidity as target in acute heart failure trials How to define the target population? Marco Metra, Brescia The Burden of Acute HF Acute HF
More informationEffect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF) Elizabeth Tien, PharmD, BCPS PGY2 Cardiology Pharmacy Resident Moses H. Cone Memorial Hospital Greensboro, NC Kristen Pogue,
More informationCardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationIntroduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring
Introduction Invasive Hemodynamic Monitoring Audis Bethea, Pharm.D. Assistant Professor Therapeutics IV January 21, 2004 Hemodynamic monitoring is necessary to assess and manage shock Information obtained
More informationImproving Transition of Care in Congestive Heart Failure. Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare
Improving Transition of Care in Congestive Heart Failure Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare Heart Failure Fastest growing clinical cardiac disease in the United
More informationNITROGLYCERIN A NEW LOOK FOR AN OLD FRIEND. Casey Patrick MD Jordan Anderson LP, CCP-C Texas EMS November 19, 2018
NITROGLYCERIN A NEW LOOK FOR AN OLD FRIEND Casey Patrick MD Jordan Anderson LP, CCP-C Texas EMS November 19, 2018 OBJECTIVES Review pathophysiology of CHF Differentiate between acute pulmonary edema (APE),
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationObjectives. Let s start at the beginning 10/28/2014. What is Heart Failure? Understanding Heart Failure with Preserved LV Systolic Function
Understanding Heart Failure with Preserved LV Systolic Function Eric Ernst, MD Medical Director C.O.R.E. Clinic Objectives Clarify the terminology surrounding right heart failure and diastolic heart failure
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationImpact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,
More informationSelective Cardiac Myosin Activators in Heart Failure
Selective Cardiac Myosin Activators in Heart Failure John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationSerelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure
Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure Item Type info:eu-repo/semantics/article Authors Hernández, Adrian V. Citation Eur Heart J (2014) 35
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationReport on the Expert Group Meeting of Paediatric Heart Failure, London 29 November 2010
Report on the Expert Group Meeting of Paediatric Heart Failure, London 29 November Clinical trials in Paediatric Heart Failure List of participants: Michael Burch, Hugo Devlieger, Angeles Garcia, Daphne
More informationSection 12: Evaluation and Management of Patients With Acute Decompensated Heart Failure
Journal of Cardiac Failure Vol. 12 No. 1 2006 Section 12: Evaluation and Management of Patients With Acute Decompensated Heart Failure Overview Acute decompensated heart failure (ADHF) has emerged as a
More informationAldosterone Antagonist. Hyd/ISDN*
Μedical management of heart failure: Update 2014 Dr John T Parissis Attikon University Hospital Athens, Greece Disclosures: Received honoraria as consultant or research grants by Orion- Pharma, Servier,
More informationHeart Failure CTSHP Fall Seminar
Heart Failure CTSHP Fall Seminar Laurajo Ryan, PharmD, MSc, BCPS, CDE Pharmacist Learning Objectives Outline the pathophysiology of heart failure List triggers for decompensated heart failure Describe
More informationWHY ADMINISTER CARDIOTONIC AGENTS?
Cardiac Pharmacology: Ideas For Advancing Your Clinical Practice The image cannot be displayed. Your computer may not have enough memory to open the image, or Roberta L. Hines, M.D. Nicholas M. Greene
More informationEvaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationIntegrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure
Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure J. Herbert Patterson, Pharm.D., FCCP One of Four Continuing Education Programs in the Series, Acute Decompensated
More informationHeart.org/HFGuidelinesToolkit
2017 /H/HFS Focused Update of the 2013 F/H 6.3.1 Biomarkers for Prevention: Recommendation OR LOE Recommendation a For patients at risk of developing HF, natriuretic peptide biomarker-based screening followed
More informationPractical Points in Cardiorenal Syndrome
Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationCharles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT
Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT Key Messages Heart Failure is Common Heart failure is complex Heart Failure is a major issue for the NHS Heart Failure has a worse prognosis
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationCLASIFICATION OF ACUTE HEART FAILURE
CLASIFICATION OF ACUTE HEART FAILURE CLINICAL STATUS HR SBP mmhg CI L/min/m 2 PCWP mmhg Congestion Killip/Forrester Diuresis Hupoperfusion End-organ hypoperfusion I. Acute decompensated CHF +/ Low normal
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationTaking the FAILURE out of CHF Denzil Moraes, MD, FACC
Taking the FAILURE out of CHF Denzil Moraes, MD, FACC Our Lady of the Lake Heart & Vascular Institute CHAIR Heart Failure Committee The Burden of Heart Failure Prevalence of Heart Failure ~ Currently 5.7
More informationHEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida
HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication
More informationCardiorenal and Renocardiac Syndrome
And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationUsing Lung Ultrasound to Diagnose and Manage Acute Heart Failure
Using Lung Ultrasound to Diagnose and Manage Acute Heart Failure Jennifer Martindale, MD Assistant Professor Department of Emergency Medicine SUNY Downstate/Kings County Hospital Brooklyn, NY What is acute
More informationPercutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI
Percutaneous Mechanical Circulatory Support for Cardiogenic Shock 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI The Need for Circulatory Support Basic Pathophysiologic Problems:
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationCASE STUDIES IN ADVANCED HEART FAILURE
CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute, Cardiovascular Medicine DISCLOSURES NOTHING
More informationTips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance
Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationHeart Failure Dr ahmed almutairi Assistant professor internal medicin dept
Heart Failure Dr ahmed almutairi Assistant professor internal medicin dept (MBBS)(SBMD) Introduction Epidemiology Pathophysiology diastolic/systolic Risk factors Signs and symptoms Classification of HF
More informationHeart failure for syndicate
Heart failure for syndicate By M.Wafaie Aboleineen,MD,FACC ESC Guidelines for the diagnosis and treatment of heart failure Part I 1 4 2 Common ECG abnormalities in HF 3 Common CXR abnormalities in HF Common
More informationWHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES
WHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES Mrudula R Munagala, M.D., FACC CO- Director Heart Failure & Circulatory Support Program OklahomaHeart.com Heart Failure Prevalence Heart Failure affects
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationHeart failure hospitalizations with preserved or reduced ejection fraction
Clinical profile and in-hospital outcomes in patients admitted for heart failure with preserved or reduced ejection fraction. EPI-CARDIO prospective registry Tajer, C; Mariani, J; de Abreu, M; Charask,
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationDiastolic Heart Failure Uri Elkayam, MD
Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A
More informationA Study Conducted At A Tertiary Care Teaching Institute in Chennai, on The Clinical And Etiological Profile Of Patients With Acute Heart Failure.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 12 Ver. VIII (Dec. 2017), PP 27-33 www.iosrjournals.org A Study Conducted At A Tertiary Care
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationThey may forget your name, but they will never forget how you made them feel.
Relax and Learn at the Farm 2013 Presented By DNP, RN, CCNS, CCRN-CMC, CHFN Cardiovascular Nursing Education Associations 1 They may forget your name, but they will never forget how you made them feel.
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More information